Algeta ASA (OSL:ALGETA) Please find notice of an Extra Ordinary General Meeting in Algeta ASA enclosed.
The Ordinary General Meeting will be held on September 15 at 16:00 hours in Algeta ASA's premises, Kjelsåsveien 172A (ground floor), Oslo, Norway.
Printed edition of the notice is today being sent by mail to Algeta's shareholders.
For further information, please contact
Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) post@algeta.com
Øystein Soug, CFO +47 23 00 79 84 / +47 906 56 525 post@algeta.com
About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, has commenced an international phase III clinical trial in hormone-refractory prostate cancer (ALSYMPCA) based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
###
LINK: http://hugin.info/134655/R/1246926/269842.pdf
LINK: http://hugin.info/134655/R/1246926/269843.pdf
Algeta ASA
http://www.algeta.com
ISIN: NO0010239437
Stock Identifier: XOSL.ALGETA
The Ordinary General Meeting will be held on September 15 at 16:00 hours in Algeta ASA's premises, Kjelsåsveien 172A (ground floor), Oslo, Norway.
Printed edition of the notice is today being sent by mail to Algeta's shareholders.
For further information, please contact
Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) post@algeta.com
Øystein Soug, CFO +47 23 00 79 84 / +47 906 56 525 post@algeta.com
About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, has commenced an international phase III clinical trial in hormone-refractory prostate cancer (ALSYMPCA) based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
###
LINK: http://hugin.info/134655/R/1246926/269842.pdf
LINK: http://hugin.info/134655/R/1246926/269843.pdf
Algeta ASA
http://www.algeta.com
ISIN: NO0010239437
Stock Identifier: XOSL.ALGETA
| Tweet |
 |
Related Companies |
>>> Fortis |
| |
Related Industry Topics: |
European Finance News | |
| |
Diese Seite wurde besucht: (letzten 30 Tagen: 10) (seit Veröffentlichung: 1000) |
Site Search
| DEUTSCH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
